Study of Efficacy and Safety of Investigational Treatment in Patients With Nail Psoriasis

Summary

Part 1 is a randomized, double-blind, placebo-controlled phase 1b study to evaluate AT193 in approximately 34 patients with nail psoriasis for 16 weeks. Part 2 is an open-label extension phase where all patients will receive active drug for an additional 16 weeks followed by a 2 week nontreatment period.

Timeline

Start

2022-04-01

Primary completion

2023-08

Completion

2023-08

Drugs

Indications